KANTREX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kantrex, and when can generic versions of Kantrex launch?
Kantrex is a drug marketed by Apothecon and is included in six NDAs.
The generic ingredient in KANTREX is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.
Summary for KANTREX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 141 |
Clinical Trials: | 2 |
Formulation / Manufacturing: | see details |
DailyMed Link: | KANTREX at DailyMed |
Recent Clinical Trials for KANTREX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
McMaster University | N/A |
Institute of Tropical Medicine, Belgium | Phase 3 |
Medical Research Council | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for KANTREX
US Patents and Regulatory Information for KANTREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apothecon | KANTREX | kanamycin sulfate | CAPSULE;ORAL | 060516-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Apothecon | KANTREX | kanamycin sulfate | INJECTABLE;INJECTION | 061655-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Apothecon | KANTREX | kanamycin sulfate | INJECTABLE;INJECTION | 061655-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Apothecon | KANTREX | kanamycin sulfate | INJECTABLE;INJECTION | 062564-002 | Sep 21, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |